0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD19

CD19

CD19 Molecule Information

Name:B-lymphocyte antigen CD19
Target Synonym:CD19?T-cell surface antigen Leu-12?B-lymphocyte surface antigen B4?B-lymphocyte antigen CD19?Differentiation antigen CD19?CD_antigen=CD19
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:75
Lastest Research Phase:Approved

CD19 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CD9-H5258 Human Human CD19 (20-291) Protein, Mouse IgG2a Fc Tag
CD9-H5258-structure
CD9-HF251 Human FITC-Labeled Human CD19 (20-291) Protein, Fc Tag
CD9-HF251-structure
CD9-HF251-sds
CD9-HF2H2 Human FITC-Labeled Human CD19 (20-291) Protein
CD9-HF2H2-structure
CD9-HF2H2-sds
CD9-H5251 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity)
CD9-H5251-structure
CD9-H5251-sds
CD9-H5251-elisa_1
CD9-H5251-elisa_2
CD9-H5250 Human Human CD19 (20-291) Protein, Llama IgG2b Fc Tag, low endotoxin
CD9-H5250-structure
CD9-H5250-sds
CD9-H5250-elisa_1
CD9-H52H2 Human Human CD19 (20-291) Protein, His Tag
CD9-H52H2-structure
CD9-H52H2-sds
CD9-H52H2-elisa_1
CD9-H52H2-elisa_2
CD9-C5251 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, Fc Tag
CD9-C5251-structure
CD9-C5251-sds
CD9-H5255 Human Human CD19 (20-278) Protein, Fc Tag
CD9-H5255-structure
CD9-H5255-sds
CD9-H8259 Human Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling)
CD9-H8259-structure
CD9-H8259-sds
CD9-H8259-elisa_1
CD9-H5259 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin
CD9-H5259-structure
CD9-H5259-sds
CD9-H5259-elisa_1

CD19 Molecule Synonym Name

CD19,B4,CVID3,MGC12802

CD19 Molecule Background

B-lymphocyte antigen CD19 (CD19) is also known as B-lymphocyte surface antigen B4, Differentiation antigen CD19 and T-cell surface antigen Leu-12, which is a single-pass type I  membrane protein and contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 forms a complex with CD21, CD81 and CD225 in the membrane of mature B cells. CD19 interacts with GRB2 and SOS when phosphorylated on Tyr-348 and/or Tyr-378. CD19 also interacts with PLCG2 when phosphorylated on Tyr-409. CD19 is an important pan B cell marker and co-stimulatory protein in humans and mice. CD19 is a hallmark differentiation antigen of the B cell lineage and positively regulates antigen receptor signal transduction in mature B cells. CD19 defines signaling thresholds for the Ag receptor as well as other cell surface receptors that regulate B lymphocyte selection, activation, and differentiation. Defects in CD19 are a cause of hypogammaglobulinemia.

CD19 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Blinatumomab AMG-103; MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3 Approved Amgen BLINCYTO fda Acute lymphoblastic leukaemia (ALL) AMGEN 2014-12-03 Acute lymphoblastic leukaemia (ALL) Details
Tisagenlecleucel CART-019; CART-19; CTL-019; LG-740 Approved University of Pennsylvania, Novartis tisagenlecleucel ema Novartis Europharm Limited 2018-08-23 Acute lymphoblastic leukaemia (ALL) Details
Axicabtagene ciloleucel FKC876; KTE-C19 Approved Cabaret Biotech, Kite Pharma, Fosun Pharma axicabtagene ciloleucel ema Kite Pharma EU B.V. 2018-08-23 B-cell lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma Details

CD19 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AUT-O3 AUTO-3 Phase Ⅱ University College London, Autolus B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
CD19 chimeric antigen receptor T cell therapy (Takara Bio) TBI-1501 Phase Ⅱ TaKaRa Bio, Memorial Sloan-Kettering Cancer Center Non-Hodgkin's lymphoma (NHL) Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase Ⅰ Marino Biotechnology, Chengdu Galaxy Biomed, Peking University B-cell lymphoma Details
Anti-CD3-anti-CD19 bispecific monoclonal antibody (Nonindustrial source) Phase Ⅰ Nonindustrial source Non-Hodgkin's lymphoma (NHL) Details
SGN-CD19B SGN-CD19B Phase Ⅰ Seattle Genetics Non-Hodgkin's lymphoma (NHL) Details
Taplitumomab paptox Phase Ⅲ University of Minnesota Leukemia Details
aCD19z aCD19z Phase Ⅰ Christie Hospital NHS Foundation Trust, Cellular Therapeutics Non-Hodgkin's lymphoma (NHL) Details
C-CAR011 Phase Ⅱ General Hospital of the People's Liberation Army, Cellular Biomedicine Group, Shanghai saibiman biotechnology Lymphoblastic leukaemia, Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Leukemia, Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) Details
pCAR-19B IND Filing Chongqing Precision Biotech Leukemia Details
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) Phase Ⅱ Chaim Sheba Medical Center at Tel HaShomer Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
DT-2219-ARL Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein; DT-2219-ARL; OXS-1550; DT-2219ARL; DT-2219; IND-100780 Phase Ⅱ University of Minnesota, Oxis International, GT Biopharma B-cell lymphoma, Leukemia Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase Ⅰ University of Texas Southwestern Medical Center, Galileo Research B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
AUTO-1 AUTO1; AUTO-1 Phase Ⅰ University College London, Autolus Burkitt's lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR T cell therapy (Shanghai GeneChem) Phase Ⅱ Shanghai GeneChem Leukemia, Systemic lupus erythematosus Details
CD19-CART Phase Ⅱ Shanghai Hrain Biotechnology Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase Ⅱ General Hospital of the People's Liberation Army B-cell lymphoma, Leukemia Details
Anti CD19 chimeric antigen receptor T cell therapy (Gracell Biotechnology) Phase Ⅰ Gracell Biotechnology B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) Phase Ⅰ City of Hope National Medical Center Non-Hodgkin's lymphoma (NHL) Details
AFM-11 AFM-11 Phase Ⅰ Affimed Non-Hodgkin's lymphoma (NHL) Details
BinD-19 (Shenzhen BinDeBio) BinD-19 IND Filing BinDeBio Lymphoblastic leukaemia, B-cell lymphoma Details
IM19CAR-T Phase Ⅱ Beijing Immunochina Medical Science & Technology Leukemia, Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) PZ-01 Phase Not Specified Pinze Lifetechnology B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
3rd-gen-CD19-CAR 3rd-gen-CD19-CAR Phase Ⅱ bluebird bio, Celgene B-cell lymphoma, Leukemia Details
CD19 CAR-T cell (Pregene) Phase Ⅱ Pregene B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
FH-2494 FH-2494 Phase Ⅱ Fred Hutchinson Cancer Research Center, National Cancer Institute Leukemia, Lymphoma Details
MDX 1342 MDX-1342 Phase Ⅰ Medarex Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis (RA) Details
Anti-CD19 CAR T-cell therapy (University College London) 4G7-CARD Phase Ⅰ University College London Lymphoma Details
A-319 A-319,A319 Phase Ⅰ Generon Corporation B-cell lymphoma, Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL) Details
Oncolysin B Phase Ⅲ ImmunoGen Leukemia, Lymphoma, Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) Phase Ⅰ Nagoya University, Shinshu University, Japan Tissue Engineering, Fujifilm group Acute lymphoblastic leukaemia (ALL) Details
MOR-208 MOR-208; MOR-00208; XENP-5574; XmAb-5574 Phase Ⅲ Xencor, MorphoSys Chronic lymphocytic leukemia (CLL), Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) Phase Ⅰ Immune Cell, Weifang People's Hospital Lymphoblastic leukaemia, B-cell lymphoma Details
CD19 CAR-T (HuaDao CAR-Tcell) IND Filing HuaDao CAR-Tcell Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
JCAR-015 JCAR-15; JCAR-015; 19-28z CAR T cells; 19-28z+ T cells; 19-28z-T-Cells Phase Ⅱ Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene, TaKaRa Bio Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
Inebilizumab MEDI-551; 16C4-aFuc; 74T7185BMM (UNII code) Phase Ⅲ MedImmune Diffuse large B cell lymphoma, Multiple sclerosis (MS), Scleroderma, Neuromyelitis optica (NMO) Details
HuCART19 Phase Ⅰ Kite Pharma, National Cancer Institute B-cell malignancies Details
Denintuzumab mafodotin SGN-19A; SGN-CD19A Phase Ⅱ Seattle Genetics Diffuse large B cell lymphoma, Follicular lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
CTL-119 CTL-119 Phase Ⅰ University of Pennsylvania, Novartis Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) Phase Ⅱ Hrain Biotechnology, Fudan University Zhongshan Hospital Diffuse large B cell lymphoma, Follicular lymphoma Details
Coltuximab ravtansine SAR-3419; huB4-DM4 Phase Ⅱ ImmunoGen, Sanofi Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
AMG-562 AMG-562 Phase Ⅰ Amgen Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase Ⅰ Tianjin Mycure Medical Technology Acute lymphoblastic leukaemia (ALL) Details
19-28z+ 19-28z+ Phase Ⅱ Memorial Sloan-Kettering Cancer Center, Dana-Farber Cancer Institute Leukemia Details
UCART-19 UCART-19; S-68587 Phase Ⅰ Cellectis, Pfizer, Servier Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL) Details
CD19-CAR CD19-CAR Phase Ⅰ M.D. Anderson Cancer Center, Ziopharm Oncology, Intrexon Corporation Leukemia, Lymphoma Details
CD19.CAR-VST CD19.CAR-VST Phase Ⅰ Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase Ⅰ Stanford University B-cell lymphoma Details
TI-1007 (Timmune Biotech) TI-1007,TI 1007,TI1007 Phase Ⅱ Timmune Biotech Non-Hodgkin's lymphoma (NHL) Details
CD19-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) IND Filing Unicar-Therapy Bio-medicine Technology Lymphoma Details
JWCAR-029 JWCAR-029,JWCAR029; JWCAR 029 Phase Ⅰ Shanghai Mingju Biological Technology Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) Phase Ⅰ Juno Therapeutics Chronic lymphocytic leukemia (CLL) Details
JCAR-014 JCAR-014 Phase Ⅱ Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
Anti-CD19 CAR-T cell therapy (Bioceltech) Phase Not Specified Bioceltech Therapeutics Acute lymphoblastic leukaemia (ALL) Details
ET190L1-ARTEMIS T cells (Eureka Therapeutics) ET-190; ET190; ET190L1; ET190L1-ARTEMI Phase Ⅰ Eureka therapeutics, Duke University Chronic lymphocytic leukemia (CLL), B-cell lymphoma, Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) Phase Ⅱ Hebei Senlang BIOTECHNOLOGY Co., LTD B-cell lymphoma, hematological malignancies Details
Monoclonal antibody B43 Genistein-conjugate Phase Ⅰ University of Minnesota, Bristol-Myers Squibb Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
DI-B4 DI-B4 Phase Ⅰ Cancer Research UK, Merck Serono B-cell lymphoma, Chronic lymphocytic leukemia (CLL) Details
Anti-CD19 chimeric antigen receptor T cell therapy (Yake) YK-C19 Phase Not Specified Yake Biotechnology Lymphoblastic leukaemia, B-cell lymphoma Details
Lisocabtagene maraleucel (Celgene/Juno Therapeutics) JCAR-017 Phase Ⅲ Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene Non-Hodgkin's lymphoma (NHL) Details
Modified anti-CD19 T-cell therapy (Fred Hutchinson Cancer Research Center) Phase Ⅰ Fred Hutchinson Cancer Research Center B-cell malignancies Details
CD19/CD3 Preclinical YZY Bio Lymphoma Details
EBV-CTL (Atara/MSKCC) EBV-CTL-Atara-MSKCC Preclinical Memorial Sloan-Kettering Cancer Center, Atara Biotherapeutics EBV-associated post-transplant lymphoproliferative disease (PTLD) Details
Chimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene) BG-T19 Phase Ⅰ Guangzhou Bio-gene Technology Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
AMG-729 XmAb-5871; AMG-729 Phase Ⅱ Xencor Autoimmune diseases, Systemic lupus erythematosus, Rheumatoid arthritis (RA) Details
因诺卡替-19细胞 IND Filing Shenzhen Innovation Immunotechnology Lymphoblastic leukaemia Details
Duvortuxizumab JNJ-64052781; MGD-011 Phase Ⅰ MacroGenics, Janssen Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), hematological malignancies, Follicular lymphoma, Malignancies Details
Loncastuximab tesirine ADCT-402 Phase Ⅱ ADC Therapeutics Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
PCAR-119 (PersonGen Biomedicine) PCAR-119,PCAR 119,PCAR119 Phase Ⅱ PersonGen Biomedicine Leukemia, Lymphoma Details
CAR-CD19 T cell therapy CT-032,CT032; CT 032 Phase Ⅰ CARsgen B-cell lymphoma, Leukemia Details
Anti-CD19 CAR-T cell therapy (Sinobioway) Phase Ⅱ Sinobioway Biomedicine Diffuse large B cell lymphoma, Lymphoma Details
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) IND Filing Unicar-Therapy Bio-medicine Technology Acute lymphoblastic leukaemia (ALL), Central nervous system leukemia Details
H-31970-SAGAN H-31970-SAGAN Phase Ⅰ Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) Phase Ⅱ Innovative Cellular Therapeutics, Zhejiang University, Kunming Medical University Lymphoblastic leukaemia, Diffuse large B cell lymphoma, B-cell lymphoma, Leukemia, Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 chimeric antigen receptor T cell therapy (Union Stem Cell and Gene Engineering) Phase Ⅰ Zhongyuan Union Stem Cell Bio-Engineering B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
PCAR-019 (Anke Biotechnology) Phase Ⅱ Anke Biotechnology Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details

This web search service is supported by Google Inc.

totop